Genetic Origins of Adverse Outcomes in African Americans with Lymphoma

摘要 弥漫性大B细胞淋巴瘤(DLBCL)是最常见的血癌形式，其特征是 显著的遗传异质性。一段时间以来，人们就知道非洲裔美国人的患者 比高加索患者的预后更差。在修正了社会经济学和社会经济学中的潜在差异后 获得护理，我们的数据表明，非裔美国人的不良结局主要是由不同的 他们肿瘤的遗传学。这些较差结果的潜在遗传原因尚未被研究。 系统地。在这里，我们建议研究非裔美国人的肿瘤和生殖系遗传学 全面了解他们较差结果的遗传基础。白粉菌的基因组初步分析 非裔美国人DLBCL患者发现更频繁的组蛋白甲基转移酶基因突变 和其他基因。在这项建议中，我们试图全面定义不良结局的遗传来源 患有DLBCL的非裔美国人，并对选定的基因组改变进行功能表征。

ABSTRACT Diffuse large B cell lymphoma (DLBCL) is the most common form of blood cancer and is characterized by a striking degree of genetic heterogeneity. It has been known for some time that African American patients have poorer outcomes than Caucasian patients. After correcting for potential differences in socioeconomics and access to care, our data indicate that the poorer outcomes in African Americans arise primarily from distinct genetics of their tumors. The underlying genetic causes of these poorer outcomes have not been studied systematically. Here, we propose to investigate tumor and germline genetics of African Americans to comprehensively understand the genetic basis of their poorer outcomes. Preliminary genomic analysis of African American DLBCL patients has revealed more frequent mutations in histone methyltransferase genes and other genes. In this proposal, we seek to comprehensively define the genetic origins of poor outcomes in African Americans with DLBCL and perform functional characterization of selected genomic alterations.